NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+39.41%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$82.4M
AUM Growth
+$82.4M
(-46%)
Cap. Flow
-$116M
Cap. Flow
% of AUM
-140.62%
Top 10 Holdings %
Top 10 Hldgs %
72.4%
Holding
34
New
12
Increased
–
Reduced
12
Closed
8
Top Buys
| 1 |
UroGen Pharma
URGN
|
$4.9M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$3.09M |
| 3 |
Sarepta Therapeutics
SRPT
|
$2.54M |
| 4 |
uniQure
QURE
|
$2.31M |
| 5 |
Neurocrine Biosciences
NBIX
|
$2.12M |
Top Sells
| 1 |
Novartis
NVS
|
$22.9M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$20M |
| 3 |
Insmed
INSM
|
$16.1M |
| 4 |
Bausch Health
BHC
|
$11.3M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
$10.8M |
Sector Composition
| 1 | Healthcare | 92.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOLD
1
DELISTED
Audentes Therapeutics, Inc
BOLD
| $9.78M | 11.87% | 250,620 -513,573 | -67% | -$20M |
|
2
Heron Therapeutics
HRTX
$207M
| $9.5M | 11.53% | 388,623 -430,541 | -53% | -$10.5M |
|
|
3
Insmed
INSM
$28.8B
| $8.26M | 10.03% | 284,263 -554,683 | -66% | -$16.1M |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $6.43M | 7.8% | 334,724 -559,955 | -63% | -$10.8M |
|
|
5
Bausch Health
BHC
$2.74B
| $5.08M | 6.16% | 205,660 -459,177 | -69% | -$11.3M |
|
|
6
UroGen Pharma
URGN
$900M
| $4.9M | 5.94% | +132,589 | New | +$4.9M |
|
|
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.61M | 5.59% | 87,099 -134,563 | -61% | -$7.12M |
|
|
STML
8
DELISTED
Stemline Therapeutics, Inc.
STML
| $4.18M | 5.08% | 325,526 -386,032 | -54% | -$4.96M |
|
|
9
Novartis
NVS
$245B
| $3.83M | 4.65% | 45,329 -270,788 | -86% | -$22.9M |
|
|
AMRN
10
Amarin Corp
AMRN
$311M
| $3.09M | 3.75% | +148,695 | New | +$3.09M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $2.79M | 3.39% | 210,257 -504,507 | -71% | -$6.7M |
|
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $2.54M | 3.08% | +21,270 | New | +$2.54M |
|
|
13
uniQure
QURE
$896M
| $2.31M | 2.81% | +38,800 | New | +$2.31M |
|
14
Exelixis
EXEL
$10.1B
| $2.15M | 2.61% | 90,356 -217,383 | -71% | -$5.17M |
|
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $2.12M | 2.57% | +24,040 | New | +$2.12M |
|
|
ACOR
16
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $2.06M | 2.5% | +154,806 | New | +$2.06M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $2.01M | 2.43% | +13,700 | New | +$2.01M |
|
|
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.34M | 1.62% | +11,952 | New | +$1.34M |
|
19
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.22M | 1.48% | +67,692 | New | +$1.22M |
|
|
CHMA
20
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $1.06M | 1.29% | 203,948 -862,491 | -81% | -$4.49M |
|
|
DCPH
21
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $995K | 1.21% | 42,865 -79,027 | -65% | -$1.83M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $986K | 1.2% | +6,200 | New | +$986K |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $733K | 0.89% | +8,250 | New | +$733K |
|
24
Madrigal Pharmaceuticals
MDGL
$9.76B
| $432K | 0.52% | +3,452 | New | +$432K |
|
25
Gyre Therapeutics
GYRE
$703M
| – | – | -376,010 | Closed | -$2.97M |
|